Paclitaxel neurotoxicity: Clinical and neurophysiological study of 23 patients

A. Pace, L. Bove, A. Aloe, M. Nardi, A. Pietrangeli, F. Calabresi, P. Innocenti, B. Jandolo

Research output: Contribution to journalArticlepeer-review


Paclitaxel is the prototype of a new class of chemotherapeutic agents with an antimitotic effect that is related to its ability to interfere with the microtubule system. It causes peripheral neurological toxicity by means of its activity on the axonal microtubules. To define the clinical and neurophysiological characteristics of paclitaxel neuropathy 23 patients undergoing paclitaxel therapy at a dose of 175 mg/m2 were studied. The patients were divided into two groups, with only one group receiving pretreatment with potentially neurotoxic drugs such as cisplatin and carboplatin. The results showed a high incidence of mild neurotoxicity in both groups. The clinical and neurophysiological data make it possible to define paclitaxel neurotoxicity as a distal axonal neuropathy with a summatory effect in patients pretreated with cisplatin; the possible reversibility of paclitaxel neurotoxicity requires further confirmation.

Original languageEnglish
Pages (from-to)73-79
Number of pages7
JournalItalian Journal of Neurological Sciences
Issue number2
Publication statusPublished - 1997


  • distal axonopathy
  • neurotoxicity
  • paclitaxel
  • platinum-compounds

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Psychiatry and Mental health
  • Dermatology


Dive into the research topics of 'Paclitaxel neurotoxicity: Clinical and neurophysiological study of 23 patients'. Together they form a unique fingerprint.

Cite this